Preferred therapies for neovascular age-related macular degeneration
- 1 May 2012
- journal article
- review article
- Published by Ovid Technologies (Wolters Kluwer Health) in Current Opinion in Opthalmology
- Vol. 23 (3), 182-188
- https://doi.org/10.1097/icu.0b013e328352411c
Abstract
This report reviews the current treatment strategies and the most recent clinical trials in the treatment of neovascular age-related macular degeneration. The functional and anatomic outcomes achieved in the pivotal ranibizumab trials with monthly injections set the standard for comparison. Since then, various modified dosing regimens with the aim of lessening the treatment burden associated with monthly injections have been investigated. Additionally, level I evidence now exists for the noninferiority of bevacizumab, as compared to ranibizumab, in the treatment of neovascular age-related macular degeneration (AMD) through 1 year of follow-up. Aflibercept has emerged as a new anti- vascular endothelial growth factor (VEGF) therapy showing encouraging treatment results at 1 year. Novel treatments combined with anti-VEGF agents such as localized radiation are currently being investigated. Anti-VEGF monotherapy remains the preferred therapy for the management of neovascular AMD at the present time. Aflibercept is a new, FDA-approved, effective, anti-VEGF agent available for clinical use. Ongoing clinical trials will help determine the optimal dosing regimens for all of these agents, as well as the long-term efficacy and safety of combination therapy modalities.Keywords
This publication has 63 references indexed in Scilit:
- Let us wake the nation on the treatment for age-related macular degenerationCurrent Opinion in Opthalmology, 2010
- Ranibizumab versus Verteporfin Photodynamic Therapy for Neovascular Age-Related Macular Degeneration: Two-Year Results of the ANCHOR StudyOphthalmology, 2009
- Cigarette Smoking and Age-Related Macular Degeneration in the EUREYE StudyOphthalmology, 2007
- Ranibizumab versus Verteporfin for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Ranibizumab for Neovascular Age-Related Macular DegenerationNew England Journal of Medicine, 2006
- Age-related macular degeneration: economic burden and value-based medicine analysisCanadian Journal of Ophthalmology, 2005
- Age-Related Macular Degeneration Is the Leading Cause of Blindness . . .JAMA, 2004
- The biology of VEGF and its receptorsNature Medicine, 2003
- Increased expression of angiogenic growth factors in age-related maculopathyBritish Journal of Ophthalmology, 1997
- Laser Photocoagulation of Subfoveal Recurrent Neovascular Lesions in Age-Related Macular DegenerationAmerican Journal of Ophthalmology, 1991